Part D formulary changes
CMS will accept negative formulary change requests from Medicare Part D plan sponsors for the 2007 benefit year until July 31, but the agency can only guarantee that what are considered to be "maintenance" change requests will be reviewed, according to a June 20 1memo to sponsors. Maintenance revisions might include moving a brand name product to a less preferred tier after a generic version is approved or changes for safety reasons. The agency also will allow sponsors to request certain types of changes from Aug. 8-10 in the Part D formularies that have already been submitted for 2008. "Allowable" changes specified in the memo include deletion of a drug along with the corresponding addition of a drug within the same USP class at the same, or lower, beneficiary cost-sharing level...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”